AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2234874 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol/codeine/caffeine combination (Solpadeine) (25 patients)
Number of subjects: 103
Study 2234874 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrocodeine (26 patients)
Number of subjects: 103
Study 376074 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian irradiation (2000 rads in 5 days)
Number of subjects: 705
Study 376074 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian irradiation (2000 rads in 5 days) plus prednisone, 7.5 mg daily
Number of subjects: 705
Study 376074 — intervention group
Group type: COMPARATOR
Intervention: No further therapy (Control)
Number of subjects: 705
Study 31865544 — intervention group
Group type: COMPARATOR
Intervention: CHOICE program offered by itself
Number of subjects: 0
Study 31865544 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOICE program offered with GTO implementation support
Number of subjects: 0
Study 31865544 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOICE program with GTO support
Number of subjects: 0
Study 29873278 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavior therapy (iCBT) for chronic tinnitus
Number of subjects: 0
Study 29316383 — intervention group
Group type: EXPERIMENTAL
Intervention: PRE‐RA Plus (PRE‐RA and a one‐on‐one session with a trained health educator)
Number of subjects: 238
Study 29316383 — intervention group
Group type: EXPERIMENTAL
Intervention: PRE‐RA (PRE‐RA alone)
Number of subjects: 238
Study 29316383 — intervention group
Group type: COMPARATOR
Intervention: Comparison (standard RA education)
Number of subjects: 238
Study 23160488 — intervention group
Group type: EXPERIMENTAL
Intervention: omega‐6 once daily
Number of subjects: 40
Study 23160488 — intervention group
Group type: COMPARATOR
Intervention: methylphenidate
Number of subjects: 40
Study 26168277 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute sleep deprivation (TSD)
Number of subjects: 15
Study 23307203 — intervention group
Group type: EXPERIMENTAL
Intervention: Limbal‐conjunctival autograft transplant
Number of subjects: 224
Study 23307203 — intervention group
Group type: COMPARATOR
Intervention: Conjunctival autograft transplant
Number of subjects: 224
Study 21736785 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated green tea extract (DGT; 530 mg containing about 400 mg total catechins/capsule, twice daily)
Number of subjects: 0
Study 21736785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21736785 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated green tea extract (DGT)
Number of subjects: 0
Study 21736785 — intervention group
Group type: EXPERIMENTAL
Intervention: COMT Val/Met genotype
Number of subjects: 0
Study 18676202 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade cold (4 degrees C) blood cardioplegia (Group A)
Number of subjects: 87
Study 18676202 — intervention group
Group type: COMPARATOR
Intervention: Combined antegrade-retrograde cardioplegia (Group B)
Number of subjects: 87
Study 16298018 — intervention group
Group type: EXPERIMENTAL
Intervention: Context-free implicit evaluations of GM foods using the Go No-Go task
Number of subjects: 0
Study 16298018 — intervention group
Group type: EXPERIMENTAL
Intervention: Context-dependent evaluations of GM foods in the context of ordinary and organic foods
Number of subjects: 0
Study 16298018 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit attitudes towards GM foods using semantic differential scales
Number of subjects: 0
Study 14623528 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg
Number of subjects: 0
Study 14623528 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen 20 mg
Number of subjects: 0
Study 11244517 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational atherectomy
Number of subjects: 0
Study 11244517 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional coronary atherectomy
Number of subjects: 0
Study 11244517 — intervention group
Group type: EXPERIMENTAL
Intervention: Excimer laser coronary angioplasty
Number of subjects: 0
Study 11244517 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 0
Study 11244517 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunct balloon angioplasty
Number of subjects: 0
Study 9189106 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin (12 mg/kg intravenously)
Number of subjects: 134
Study 9189106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 9189106 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 134
Study 8463989 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 23
Study 8463989 — intervention group
Group type: COMPARATOR
Intervention: Strength training
Number of subjects: 23
Study 2859780 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 121
Study 30624344 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (1800 mg/day)
Number of subjects: 32
Study 30624344 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo or alternative treatment during the crossover)
Number of subjects: 32
Study 28951525 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g mixed eicosapentaenoic acid/docosahexaenoic acid in soft-gel capsules
Number of subjects: 22
Study 28951525 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g mixed eicosapentaenoic acid/docosahexaenoic acid in Smartfish drinks
Number of subjects: 22
Study 28951525 — intervention group
Group type: EXPERIMENTAL
Intervention: Both omega-3 PUFA formulations
Number of subjects: 22
Study 27505117 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation
Number of subjects: 53
Study 27505117 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (control)
Number of subjects: 53
Study 26068234 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Vitamin D3 supplementation
Number of subjects: 74
Study 26068234 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 74
Study 23399627 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin sponge and drainage (group A)
Number of subjects: 112
Study 23399627 — intervention group
Group type: COMPARATOR
Intervention: Drainage alone (group B)
Number of subjects: 112
Study 19650808 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional anticoagulation (heparin pre-filter plus post-filter protamine) plus antiaggregation (pre-filter prostacyclin) [Group 1 (G1)]
Number of subjects: 110
Study 19650808 — intervention group
Group type: COMPARATOR
Intervention: Systemic heparin anticoagulation without antiaggregation [Group 2 (G2)]
Number of subjects: 110
Study 18369171 — intervention group
Group type: EXPERIMENTAL
Intervention: NXY-059
Number of subjects: 5028
Study 18369171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5028
Study 16463861 — intervention group
Group type: EXPERIMENTAL
Intervention: MgSO4 80 mmol/day
Number of subjects: 45
Study 16463861 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 45
Study 12851303 — intervention group
Group type: EXPERIMENTAL
Intervention: PT-141
Number of subjects: 0
Study 10357429 — intervention group
Group type: EXPERIMENTAL
Intervention: 24% sucrose solution
Number of subjects: 60
Study 10357429 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% aspartame solution
Number of subjects: 60
Study 10357429 — intervention group
Group type: COMPARATOR
Intervention: 24% polycose solution
Number of subjects: 60
Study 10357429 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 60
Study 7793231 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline
Number of subjects: 44
Study 7793231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 3402015 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.125 per cent with epinephrine 1:800.000 plus 50 micrograms of fentanyl (Group B)
Number of subjects: 95
Study 3402015 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.125 per cent with epinephrine 1:800.000 plus 100 micrograms of fentanyl (Group C)
Number of subjects: 95
Study 3402015 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.125 per cent with epinephrine 1:800.000 (Group A)
Number of subjects: 95
Study 31074660 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Management program plus Physical Therapy
Number of subjects: 66
Study 31074660 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Number of subjects: 66
Study 31074660 — intervention group
Group type: COMPARATOR
Intervention: Control Group (standard medical treatment)
Number of subjects: 66
Study 31842940 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab with methotrexate (IFX+MTX)
Number of subjects: 60
Study 31842940 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (methotrexate, hydroxychloroquine, and sulfasalazine)
Number of subjects: 60
Study 31842940 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate monotherapy (MTX)
Number of subjects: 60
Study 31842940 — intervention group
Group type: COMPARATOR
Intervention: All treatments combined
Number of subjects: 60
Study 29046405 — intervention group
Group type: EXPERIMENTAL
Intervention: Total potato consumption in PREDIMED (81.9 ± 40.6 g/d)
Number of subjects: 0
Study 29046405 — intervention group
Group type: EXPERIMENTAL
Intervention: Total potato consumption in SUN (52.7 ± 33.6 g/d)
Number of subjects: 0
Study 26639851 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6% Energy Trans Fatty Acids (TFA)
Number of subjects: 51
Study 26639851 — intervention group
Group type: COMPARATOR
Intervention: 0.04% Energy (Control)
Number of subjects: 51
Study 23092731 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025% S. flavescens
Number of subjects: 0
Study 23092731 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.050% S. flavescens
Number of subjects: 0
Study 23092731 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.100% S. flavescens
Number of subjects: 0
Study 23092731 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.200% S. flavescens
Number of subjects: 0
Study 23092731 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.400% S. flavescens
Number of subjects: 0
Study 23092731 — intervention group
Group type: COMPARATOR
Intervention: Control group (basal diet without S. flavescens)
Number of subjects: 0
Study 22001182 — intervention group
Group type: EXPERIMENTAL
Intervention: Antecolic reconstruction
Number of subjects: 46
Study 22001182 — intervention group
Group type: COMPARATOR
Intervention: Retrocolic reconstruction
Number of subjects: 46
Study 19092350 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hypocaloric nutrition starting 20 hours before the operation
Number of subjects: 22
Study 19092350 — intervention group
Group type: COMPARATOR
Intervention: Fasting
Number of subjects: 22
Study 21823168 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dose of olanzapine (OLZ)
Number of subjects: 26
Study 16202727 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adnexectomy
Number of subjects: 20
Study 16202727 — intervention group
Group type: COMPARATOR
Intervention: Open adnexectomy
Number of subjects: 20
Study 11898975 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior involvement in hiring
Number of subjects: 101
Study 11898975 — intervention group
Group type: COMPARATOR
Intervention: No prior involvement
Number of subjects: 101
Study 9580762 — intervention group
Group type: EXPERIMENTAL
Intervention: High-iron formula (12.7 mg/L of elemental iron)
Number of subjects: 835
Study 9580762 — intervention group
Group type: COMPARATOR
Intervention: Low-iron formula (2.3 mg/L of elemental iron)
Number of subjects: 835
Study 9580762 — intervention group
Group type: EXPERIMENTAL
Intervention: High-iron formula
Number of subjects: 835
Study 8206405 — intervention group
Group type: EXPERIMENTAL
Intervention: Groshong catheter for intraperitoneal therapy
Number of subjects: 24
Study 2968268 — intervention group
Group type: EXPERIMENTAL
Intervention: celiprolol
Number of subjects: 30
Study 2968268 — intervention group
Group type: COMPARATOR
Intervention: acebutolol
Number of subjects: 30
Study 12357164 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (n = 16)
Number of subjects: 32
Study 12357164 — intervention group
Group type: COMPARATOR
Intervention: Intravenous analgesia (n = 16)
Number of subjects: 32
Study 29685179 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of oral doxycycline (400 mg) and metronidazole (400 mg)
Number of subjects: 3400
Study 29685179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3400
Study 26661344 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-performed daily spirometry and positive expiratory pressure (PEP)
Number of subjects: 80
Study 26661344 — intervention group
Group type: COMPARATOR
Intervention: Control group (no spirometry or PEP)
Number of subjects: 80
Study 26661344 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education in spirometry and PEP
Number of subjects: 80
Study 25109873 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive aripiprazole with antidepressant
Number of subjects: 0
Study 25109873 — intervention group
Group type: COMPARATOR
Intervention: Bupropion
Number of subjects: 0
Study 22544471 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 6
Study 21119408 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (820 nm, 3 J/cm2, 300-mW output power), applied 2 times per week for a total of 10 sessions.
Number of subjects: 40
Study 21119408 — intervention group
Group type: COMPARATOR
Intervention: Occlusal splints, worn 24 hours a day for 3 months.
Number of subjects: 40
Study 21119408 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Low-level laser and Occlusal splints)
Number of subjects: 40
Study 18381578 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine treatment
Number of subjects: 11
Study 16169561 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN beta‐1a, 44 mcg subcutaneously (sc) three times weekly (tiw) (Rebif)
Number of subjects: 0
Study 16169561 — intervention group
Group type: COMPARATOR
Intervention: IFN beta‐1a, 30 mcg intramuscularly (im) once weekly (qw) (Avonex)
Number of subjects: 0
Study 11755292 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (4 IU subcutaneously every other day for three months)
Number of subjects: 16
Study 11755292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11720604 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 32 mg once daily
Number of subjects: 332
Study 11720604 — intervention group
Group type: COMPARATOR
Intervention: Losartan 100 mg once daily
Number of subjects: 332
Study 11720604 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 332
Study 8546999 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral liarozole at a daily dose of 75 mg b.i.d. for 12 weeks, with possible increase to 150 mg b.i.d. after 1 month if no improvement
Number of subjects: 31
Study 8546999 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral liarozole
Number of subjects: 31
Study 2132454 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental rinse
Number of subjects: 0
Study 2132454 — intervention group
Group type: COMPARATOR
Intervention: Placebo rinse
Number of subjects: 0
Study 2132454 — intervention group
Group type: COMPARATOR
Intervention: Conventional mouthwash
Number of subjects: 0
Study 381957 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticrynafen (250‐‐500 mg/day)
Number of subjects: 526
Study 381957 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (50‐‐100 mg/day)
Number of subjects: 526
Study 31544279 — intervention group
Group type: EXPERIMENTAL
Intervention: SRCfield
Number of subjects: 17
Study 31544279 — intervention group
Group type: EXPERIMENTAL
Intervention: CRfield
Number of subjects: 17
Study 31544279 — intervention group
Group type: EXPERIMENTAL
Intervention: SRCdyna
Number of subjects: 17
Study 31544279 — intervention group
Group type: EXPERIMENTAL
Intervention: CRdyna
Number of subjects: 17
Study 31547286 — intervention group
Group type: EXPERIMENTAL
Intervention: Noticing urban nature
Number of subjects: 582
Study 31547286 — intervention group
Group type: COMPARATOR
Intervention: Built spaces (active control)
Number of subjects: 582
Study 27470470 — intervention group
Group type: EXPERIMENTAL
Intervention: Reach-to-Grasp training (14 one-hour therapist visits over 6 weeks, plus one hour self-practice per day)
Number of subjects: 47
Study 27470470 — intervention group
Group type: COMPARATOR
Intervention: Usual care (10.5 therapist visits, 38.6 minutes of arm therapy, 16 repetitions of functional tasks per visit)
Number of subjects: 47
Study 27470470 — intervention group
Group type: EXPERIMENTAL
Intervention: Reach-to-Grasp training
Number of subjects: 47
Study 27470470 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 47
Study 27470470 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 47
Study 26177655 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-42847922 (3-30 mg/kg)
Number of subjects: 0
Study 26177655 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-42847922
Number of subjects: 0
Study 23920052 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser acupuncture to LR8
Number of subjects: 16
Study 23920052 — intervention group
Group type: COMPARATOR
Intervention: Needle acupuncture to LR8
Number of subjects: 16
Study 21282343 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilio-pancreatic diversion (BPD)
Number of subjects: 110
Study 21282343 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control)
Number of subjects: 110
Study 19255229 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flexion cruciate-retaining knee prosthesis
Number of subjects: 100
Study 19255229 — intervention group
Group type: COMPARATOR
Intervention: Standard cruciate-retaining knee prosthesis
Number of subjects: 100
Study 16459124 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical rehabilitation programme using auditory cues
Number of subjects: 9
Study 16459124 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 9
Study 14581115 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.05 or 0.1 microg/kg/min)
Number of subjects: 13
Study 14581115 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.01 mg/kg)
Number of subjects: 13
Study 14581115 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 13
Study 11061771 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (0.2 mg/kg/dose 3 times/day)
Number of subjects: 120
Study 11061771 — intervention group
Group type: COMPARATOR
Intervention: Control (no cisapride)
Number of subjects: 120
Study 8659936 — intervention group
Group type: EXPERIMENTAL
Intervention: 37 degrees C, 90% RH
Number of subjects: 21
Study 8659936 — intervention group
Group type: COMPARATOR
Intervention: 20 degrees C, 30% RH
Number of subjects: 21
Study 8659936 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen challenge after both conditions
Number of subjects: 21
Study 1454835 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrine
Number of subjects: 2
Study 1454835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 6512867 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Couple Therapy
Number of subjects: 23
Study 6512867 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Therapy
Number of subjects: 23
Study 6512867 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal Contact Bibliotherapy (self‐help)
Number of subjects: 23
Study 31687394 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-Body Electromyostimulation (WB-EMS)
Number of subjects: 110
Study 31687394 — intervention group
Group type: COMPARATOR
Intervention: Conventional Training (CT)
Number of subjects: 110
Study 30305160 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumen-apposing metal stents (LAMS)
Number of subjects: 256
Study 30305160 — intervention group
Group type: COMPARATOR
Intervention: Double pigtail plastic stents (DPPS)
Number of subjects: 256
Study 25786348 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborn excess weight loss (EWL) defined as loss of >10% of birthweight
Number of subjects: 1107
Study 25786348 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers of infants with EWL
Number of subjects: 1107
Study 25786348 — intervention group
Group type: COMPARATOR
Intervention: Mothers of infants without EWL
Number of subjects: 1107
Study 25786348 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers with milk supply concern at 2 weeks
Number of subjects: 1107
Study 24844747 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg oral tiagabine
Number of subjects: 12
Study 24844747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 22825365 — intervention group
Group type: EXPERIMENTAL
Intervention: Larazotide acetate (0.25, 1, 4, or 8 mg)
Number of subjects: 86
Study 22825365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 22825365 — intervention group
Group type: EXPERIMENTAL
Intervention: Larazotide acetate
Number of subjects: 86
Study 20116087 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg) and acetyl salicylic acid (100 mg) after coronary stenting for myocardial infarction
Number of subjects: 66
Study 18050208 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg twice weekly
Number of subjects: 682
Study 18050208 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate ≤20 mg weekly
Number of subjects: 682
Study 18050208 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of etanercept and methotrexate
Number of subjects: 682
Study 18050208 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 682
Study 16181235 — intervention group
Group type: EXPERIMENTAL
Intervention: LGH (0.10 mg/day)
Number of subjects: 25
Study 16181235 — intervention group
Group type: EXPERIMENTAL
Intervention: SGH (mean dose 0.48 mg/day)
Number of subjects: 25
Study 16181235 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 25
Study 12173120 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem
Number of subjects: 540
Study 12173120 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin-tazobactam
Number of subjects: 540
Study 9849172 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA baths (15 minutes in tap water and Ultra MOP)
Number of subjects: 45